|
List of Jounal Titles
A to Z index of Journal Title. Choose a letter.
Clinics & Drug Therapy
20
- Diagnosis and treatment of chronic arteriosclerosis. General remarks. Pathophysiology of chronic arteriosclerosis.
- Diagnosis and treatment of chronic arteriosclerosis. General remarks. Patient trends in Japan.
- Diagnosis and treatment of chronic arteriosclerosis. General remarks. Long-term prognosis and complication.
- Diagnosis and treatment of chronic arteriosclerosis. Diagnosis. Points of diagnosis in the initial stage. Inquiry and palpation.
- Diagnosis and treatment of chronic arteriosclerosis. Diagnosis. Test for diagnosis by exclusion.
- Diagnosis and treatment of chronic arteriosclerosis. Diagnosis. Test for definite diagnosis.
- Diagnosis and treatment of chronic arteriosclerosis. Treatment. Pharmacotherapy. Oral drug.
- Diagnosis and treatment of chronic arteriosclerosis. Treatment. Pharmacotherapy. Injection.
- Diagnosis and treatment of chronic arteriosclerosis. Treatment. Exercise therapy for intermittent claudication.
- Diagnosis and treatment of chronic arteriosclerosis. Treatment. Surgical treatment. Blood circulation reconstructive operation.
- Diagnosis and treatment of chronic arteriosclerosis. Treatment. Surgical treatment. Intravascular treatment.
- Diagnosis and treatment of chronic arteriosclerosis. Prognosis. Cooperation with the vascular surgery. Blood circulation control (mainly on general patient care after the bypass operation).
- Diagnosis and treatment of chronic arteriosclerosis. Prognosis. Cooperation with the vascular surgery. Complication prevention.
- Pharmacology for therapeutic planning. Drug for allergic rhinitis. External use.
- History of the essential drug and up-to-date problems of the rational use of drugs.
2
- QOL and endometriosis of the woman. A grasp of pathophysiology. Definition and disease concept of endometriosis.
- QOL and endometriosis of the woman. A grasp of pathophysiology. Increase in endometriosis and environmental factor.
- QOL and endometriosis of the woman. A grasp of pathophysiology. Symptoms suspected of endometriosis and differential diagnosis.
- QOL and endometriosis of the woman. Classification of the drug. Type and usage of the GnRH derivative.
- QOL and endometriosis of the woman. Classification of the drug. Treatment with the oral hormone medicine.
- QOL and endometriosis of the woman. Classification of the drug. Chinese medicine and oriental medicine therapy.
- QOL and endometriosis of the woman. Treatment and patient QOL. My therapeutic experience. (1). Cases in the twenties , and not in pregnancy.
- QOL and endometriosis of the woman. Treatment and patient QOL. My therapeutic experience. (2). Cases in the thirties, and for which endometriosis parallel to sterility treatment was indicated.
- QOL and endometriosis of the woman. Treatment and patient QOL. My therapeutic experience. (3). A case in the menopausal forties associated with exacerbation of endometriosis.
- QOL and endometriosis of the woman. Treatment and patient QOL. My therapeutic experience. (4). Cases complicated by hysteromyoma. Indication for operation and pharmacotherapy.
- QOL and endometriosis of the woman. Treatment and patient QOL. My therapeutic experience. (5). Cases for which the treatment was difficult and treatment history stretched over a long time.
- QOL and endometriosis of the woman. New management method for well-being of the woman. Centering on slow-releasing IUS of the synthetic corpus luteum hormone.
- Ciprofloxacin. Ciproxan.
- Valsartan. Diovan.
- Acitazanolast hydrate. Zepelin.
- Pharmacology for therapeutic planning. Antidiabetic. Oral agent.
3
- Measures for skin lesions observed in the elderly person. Aging and skin. Skin change with the aging.
- Measures for skin lesions observed in the elderly person. Aging and skin. ADL and skin lesions of the elderly person.
- Measures for skin lesions observed in the elderly person. Aging and skin. Skin changes observed in the elderly person to be cared.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Amyctic dermatopathy. Eczema, prurigo, pruritus cutaneus, etc.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Infectious skin diseases. Bacteria, virus, fungus, etc.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Drug eruption, and toxicoderma.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Circulatory disturbance skin diseases. Varicose vein syndrome, chronic arterial obstruction diseases, etc.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Metabolic dermatosis. Diabetes mellitus, porphyria, etc.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Skin change associated with the viscera malignant tumor. Mainly dermatomyositis, acanthosis nigricans, and Leser-Trelat syndrome.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Blister diseases. Pemphigoid, etc.
- Measures for skin lesions observed in the elderly person. Main skin diseases and measures. Animal dermatosis. Sarcoptic mange, caterpillar dermatitis, etc.
- Measures for skin lesions observed in the elderly person. Main dermatosis and measures. Decubitus.
- paroxetin hydrochloride hydrate. Paxil.
- levocabastine hydrochloride. Livostin.
- activated protein C. Anact C.
- Pharmacology for therapeutic planning. Antidiabetic. Insulin preparation.
- From the consultation room. [55]. Motive for medical examination from the viewpoint of diagnosed large bowel cancer.
4
- Knowledge of new drugs in 2001 for the clinician. This 1 year on the new drug.
- Bupivacaine hydrochloride. Marcain spinal isobaric hyperbaric.
- Clobazam. Mystan tablet fine granule.
- Zolpidem tartrate. Myslee tablet.
- Paroxetine hydrochloride hydrate. Paxil tablet.
- Botulinum toxin type A. Botox injection.
- Droxidopa. Dops capsule fine granule.
- Sumatriptan succinate. Imigran injection.
- Levofloxacin. Cravit ophthalmic solution.
- Ibudilast. Eyevinal ophthalmic solution.
- Bromfenac sodium hydrate. Bronuck ophthalmic solution.
- Levobunolol hydrochloride. Mirol ophthalmic solution.
- Acitazanolast hydrate. Zepelin ophthalmic solution.
- Levocabastine hydrochloride. Livostin eye drops.
- Pilsicainide hydrochloride. Sunrythm injection.
- Valsartan. Diovan tablet.
- Atorvastatin calcium hydrate. Lipitor tablet.
- Lafutidine. Stoger tablet.
- Polycarbophil calcium. Colonel tablet fine granule.
- Clarithromycin. Klaricid tablet. Clarith tablet.
- Granisetron hydrochloride. Kytril injection.
- Goserelin acetate. Zoladex depot.
- Maxacalcitol. Oxarol injection.
- Liranaftate. Zefnart cream.
- Diclofenac sodium. Naboal gel.
- Calcipotriol. Dovonex ointment.
- Danaparoid sodium. Orgaran injection.
- Lenograstim(genetical recombination). Neutrogin injection.
- Mexiletine hydrochloride. Mexitil capsule.
- Sodium hyaluronate. Suvenyl dispo vial.
- Cytarabine. Cylocide N injection.
- Etoposide. Lastet S capsule.
- Interferon gamma-n1. Ogamma.
- Pranlukast hydrate. Onon capsule.
- Ramatroban. Baynas tablet.
- Bepotastine besilate. Talion tablet.
- Fexofenadine hydrochloride. Allegra tablet.
- Azithromycin hydrate. Zithromac tablet capsule fine granule.
- Ciprofloxacin. Ciproxan IV.
- Zanamivir hydrate. Relenza.
- Valaciclovir hydrochloride. Valtrex tablet.
- Lamivudine. Zefix tablet.
- Delavirdine mesilate. Rescriptor tablet.
- Interferon alfa(NAMALWA). Sumiferon injection disposable syringe.
- Eptacog alfa(activated)(genetical recombination). NovoSeven.
- Taltirelin hydrate. Ceredist tablet.
- Interferon beta-1b(genetical recombination). Betaferon SC injection.
- Tacrolimus hydrate. Prograf capsule.
- Human activated protein C. Anact C.
- Iodixanol. Visipaque.
- Meglumine gadoterate. Magnescope syringe.
- Knowledge of the new drug for the clinician in 2001. Report items by permanent subcommittee of Central Pharmaceutical Affairs Council. Treatment medicine. Supplemental liquid for the dialysis filtration type artificial kidney. Bifil exclusive sodium bicarbonate supplemental liquid. Bifil exclusive sodium bicarbonate supplemental liquid.
5
- Measures for year-round allergic rhinitis. Mechanism of allergic rhinitis.
- Measures for year-round allergic rhinitis. Allergic rhinitis and other allergic disease.
- Measures for year-round allergic rhinitis. Diagnosis of allergic rhinitis.
- Measures for year-round allergic rhinitis. Patient mainly with the single rhinitis symptoms.
- Measures for year-round allergic rhinitis. Patient with other allergic symptoms. Cutis symptoms.
- Measures for year-round allergic rhinitis. Patient with other allergic symptoms. Eye symptoms.
- Measures for year-round allergic rhinitis. Schedule of desensitization therapy.
- Measures for year-round allergic rhinitis. Indication of antiallergic agent.
- Measures for year-round allergic rhinitis. Indication of steroid drug.
- Measures for year-round allergic rhinitis. Indication of vasoconstrictor.
- Measures for year-round allergic rhinitis. Indication of surgical treatment.
- Measures for year-round allergic rhinitis. Remedial cautionary notes to infant and school child patients.
- Proper use of NSAIDs. Gouty attack.
- Leukotriene receptor antagonist. Zafirlukast.
- Introduction to pharmacoeconomics. The first. Pharmacoeconomics and outcome management.
- Pharmacology for therapeutic planning. H2 receptor antagonist, and proton pump inhibitor.
6
- Ambulatory medical treatment of collagen disease. Summary of the mechanism. Pathophysiology of collagen disease. From the latest knowledge.
- Ambulatory medical treatment of collagen disease. Summary of the mechanism. Epidemiology of collagen disease. Patient number, transition, disease classification.
- Ambulatory medical treatment of collagen disease. Practical diagnosis. A case which was suspected of collagen disease, and could be diagnosed. SLE, anti-phospholipid antibody syndrome.
- Ambulatory medical treatment of collagen disease. Practical diagnosis. A case which was suspected of collagen disease, and could be diagnosed. Chronic articular rheumatism.
- Ambulatory medical treatment of collagen disease. Practical diagnosis. A case which was suspected of collagen disease, and could be diagnosed. Scleroderma, multiple myositis, dermatomyositis.
- Ambulatory medical treatment of collagen disease. Practical diagnosis. A case which was suspected of collagen disease, and could be diagnosed. Sjoegren syndrome.
- Ambulatory medical treatment of collagen disease. Practical diagnosis. A case which was suspected of collagen disease, and could be diagnosed. Behcet disease.
- Ambulatory medical treatment of collagen disease. Practical diagnosis. A case which was suspected of collagen disease, and could be diagnosed. Microscopic polyangiitis.
- Ambulatory medical treatment of collagen disease. Treatment of each disease. Current treatment strategy. SLE, anti-phospholipid antibody syndrome.
- Ambulatory medical treatment of collagen disease. Treatment of each disease. Current treatment strategy. Chronic articular rheumatism.
- Ambulatory medical treatment of collagen disease. Treatment of each disease. Current treatment strategy. Systemic scleroderma, multiple myositis - dermatomyositis.
- Ambulatory medical treatment of collagen disease. Treatment of each disease. Current treatment strategy. Sjoegren syndrome.
- Ambulatory medical treatment of collagen disease. Treatment of each disease. Current treatment strategy. Behcet disease.
- Ambulatory medical treatment of collagen disease. Treatment of each disease. Current treatment strategy. Microscopic polyangiitis.
- Ambulatory medical treatment of collagen disease. Point of the ambulant follow. Daily life guidance.
- Ambulatory medical treatment of collagen disease. Point of the ambulant follow. Disease control and pregnancy.
- From the consultation room. [56]. Analysis of the side reaction due to the intravenous administration of the antimicrobial drug.
- meloxicam. Mobic.
- olopatadine hydrochloride. Allelock.
- Method for expressing the economical efficiency of pharmacotherapy. The second. Understanding of the cost and technique for economic analysis.
- Pharmacology for therapeutic planning. ACE inhibitor, AII receptor antagonist.
- Evaluation guideline of medical information for the consumer. Concerning mainly DISCERN,QUICK,CASP.
7
- How is parkinsonism dealt with? Diagnosis of Parkinson disease.
- How is parkinsonism dealt with? Diagnosis of neurodegenerative diseases presenting parkinsonism.
- How is parkinsonism dealt with? Diagnosis of symptomatic parkinsonism.
- How is parkinsonism dealt with? Parkinsonism for the primary care doctor.
- How is parkinsonism dealt with? Patient file. (1). A case of Parkinson disease having the medical record in which wearing-off phenomena and hallucination were worried for about 15 years.
- How is parkinsonism dealt with? Patient file. (2). Two cases of the progressive supranuclear palsy for which the dopamine agonist was effective.
- How is parkinsonism dealt with? Patient file. (3). A case of the typical Parkinson disease findings in which tremor exhibiting an extreme crosswise difference lasted.
- How is parkinsonism dealt with? Patient file. (4). A case of repeated neuroleptic malignant syndrome.
- How is parkinsonism dealt with? Patient file. (5). Two cases of parkinsonism for which the statistical cerebral blood flow SPECT was used and the usefulness of the differential diagnosis was examined.
- How is parkinsonism dealt with? Parkinson disease and nursing care insurance.
- Protective effects against the hypoxic intestine mucous injury by olprinone.
- From the diagnosis room. [57]. Concerning the treatment of diabetes mellitus by the practicing physician.
- Challenge of the hospital pharmacy in the home hospice care.
- Perospirone hydrochloride hydrate.
- Introduction to pharmacoeconomics. The third. Outline of the cost - benefit analysis and the application.
- Antithrombotic drug. Anticoagulant. Pharmacology for therapeutic planning.
- Talk of the genome to be understood. 1. Talk of genome and gene. Mainly human genome. 1.
8
- Antidepressant. Effective combination therapy according to the patient. Significance and cautionary notes of pharmacotherapy in the treatment start of depression.
- Antidepressant. Effective combination therapy according to the patient. Significance and cautionary notes of pharmacotherapy in the treatment continuation of depression.
- Antidepressant. Effective combination therapy according to the patient. Cautions to be done by the medical treatment person in order to prevent the dropout.
- Antidepressant. Effective combination therapy according to the patient. The cautionary note in combined use of the two antidepressants.
- Antidepressant. Effective combination therapy according to the patient. The cautionary note in combined use of the antidepressant with the other psychotropic drug.
- Antidepressant. Effective combination therapy according to the patient. The cautionary note in combined use of the antidepressant to the circulatory drug-taking patient.
- Antidepressant. Effective combination therapy according to the patient. The cautionary note in combined use of the antidepressant to the gastrointestinal drug-taking patient.
- Antidepressant. Effective combination therapy according to the patient. The cautionary note in combined use of the antidepressant to the patient taking the drug for respiratory system.
- Antidepressant. Effective combination therapy according to the patient. The cautionary note in combined use of the antidepressant to the patient taking the drug for rheumatism and collagen disease.
- Antidepressant. Effective combination therapy according to the patient. Positioning of the antidepressant in the psychosomatic internal medicine and the mental clinic.
- Antidepressant. Effective combination therapy according to the patient. Positioning of the antidepressant in the general clinic.
- Practical cancer pain treatment seen in the cases. The first. Fundamental matters and treatment of comparatively mild nociceptive pain.
- Edaravone. Radicut.
- Method for expressing the economical efficiency of pharmacotherapy. The fourth. Outline and practice of cost-benefit analysis.s
- Pharmacology for therapeutic planning. Antithrombotic drug. Antiplatelet drug.
9
- Irritable bowel syndrome. Practical diagnosis and treatment. What kind of disease is the irritable bowel syndrome?
- Irritable bowel syndrome. Practical diagnosis and treatment. How is irritable bowel syndrome diagnosed? Transition of diagnostic criteria.
- Irritable bowel syndrome. Practical diagnosis and treatment. How is irritable bowel syndrome treated? Mainly new guideline.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the patient with strong diarrhea.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the patient with strong constipation.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the patient with strong abdominal pain.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the patient with strong abdominal distension.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the patient associated with the depression tendency.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the patient with the underlying disease.
- Irritable bowel syndrome. Practical diagnosis and treatment. Prescription and life guidance to the infant patient.
- Irritable bowel syndrome. Practical diagnosis and treatment. Perspective of new drugs and treatment for irritable bowel syndrome.
- Irritable bowel syndrome. Practical diagnosis and treatment. Patient QOL as evaluation criteria.
- Property examination of the various immunoglobulin preparations for the intravenous infusion.
- History until the supply stop of the phenacetin combination pharmaceutical and problems of combination pharmaceuticals.
- Ropivacaine hydrochloride hydrate. Anapeine.
- Method for expressing the economical efficiency of pharmacotherapy. The fifth. Outline and practice of the cost-utility analysis.
- Pharmacology for therapeutic planning. Non-steroidal anti-inflammatory analgesic. Internal use. (1).
- The talk of the genome to be known. 2. Human chromosomal decoding completion of chromosome the 21st and the 22nd and the significance.
10
- Primary care for herpes zoster. For no residual PHN. Disease states and basis of the treatment of herpes zoster.
- Primary care for herpes zoster. For no residual PHN. Importance of the inquiry listening. Onset due to overwork and stress to mind and body should not be missed.
- Primary care for herpes zoster. For no residual PHN. Systemic combination therapy for herpes zoster with antiviral agent and steroid medicine. Including measures for PHN by the regional sensory nerve local anesthesia (block).
- Primary care for herpes zoster. For no residual PHN. Importance of the early diagnosis, and effectiveness of lidocaine cream and capsaicine salve for herpes zoster associated pain.
- Primary care for herpes zoster. For no residual PHN. Mainly measures for the hospitalized case.
- Primary care for herpes zoster. For no residual PHN. Importance of measures for symptomatic neuralgia and systemic administration of sufficient dose of antiviral agent.
- Primary care for herpes zoster. For no residual PHN. Appropriate administration and dosage of the antiviral agent and positive guidance to the daily life after the anthema cure.
- Primary care for herpes zoster. For no residual PHN. How is PHN prevented? PHN including the origin.
- Primary care for herpes zoster. For no residual PHN. Practice of the prescription according to the progression stage and the degree of seriousness.
- Primary care for herpes zoster. For no residual PHN. Focusing on the importance of the acute phase pain control for not leaving PHN.
- Primary care for herpes zoster. For no residual PHN. Treatment of PHN.
- Primary care for herpes zoster. For no residual PHN. Herpes zoster and drug.
- Practice of the cancer pain treatment. The second. Treatment of the moderate to grave nociceptive pain.
- Expectation to the drug economical research in Japan.
- Is bolus administration of olprinone hydrochloride during the heart-lung machine desorption effective in peripheral circulation improvement after the heart-lung machine desorption?
- Effects of precedence therapy of olprinone hydrochloride on cardiac function, extubation time, and ICU sojourn time in the coronary artery bypass operation.
- Usefulness of the administration of olprinone hydrochloride for hemodynamics and the cardiac function in the coronary artery bypass surgery under the heartbeat.
- Vasodilator action of olprinone hydrochloride used for the coronary artery bypass operation on the radial artery.
- Olprinone does not suppress HPV in the non-thoracotomy dog.
- Effect of PDEIII inhibitor on respiratory muscle fatigue.
- Continuous administration of a small amount of olprinone improves the diaphragm fatigue.
- Effect of the transtracheal administration of olprinone hydrochloride on the diaphragm fatigue.
- Effect of PDEIII inhibitor on pulmonary hypertension and on the airway contraction.
- Comparison of the airway dilator effect of olprinone and aminophylline on the airway contraction due to methacoline in the hybrid adult dog.
- Trafermin(Genetical Recombination). Fiblast.
- Falecalcitriol. Fulstan. Hornel.
- Pharmacology for therapeutic planning. Non-steroidal anti-inflammatory analgesic. Internal use. (2).
- Method for expressing the economical efficiency of pharmacotherapy. The sixth. Outline and practice of the cost - minimization analysis.
11
- Effect of drug and food on the test value. Changes of the recent eating habit and the features.
- Effect of drug and food on the test value. Definition of the health functional food and the characteristics.
- Effect of drug and food on the test value. Definition of the OTC drug and the characteristics.
- Effect of drug and food on the test value. Things affected by drug and food. Examination of urine and feces.
- Effect of drug and food on the test value. Things affected by drug and food. Hematologic test.
- Effect of drug and food on the test value. Things affected by drug and food. Clinical chemical test.
- Effect of drug and food on the test value. Things affected by drug and food. Immunoserologic examination.
- Effect of drug and food on the test value. Things affected by drug and food. Endocrine test.
- Effect of drug and food on the test value. Things affected by drug and food. Microorganism test and others.
- Montelukast sodium.
- Insulin lispro. Genetical recombination.
- Pharmacology for therapeutic planning. Macrolide antibiotics.
12
- For the new treatment of headache. Understanding of headache. Pathophysiology. Idiopathic headache and symptomatic headache.
- For the new treatment of headache. Diagnosis in the primary care. Expression type of headache as the chief complaint.
- For the new treatment of headache. Diagnosis in the primary care. Points to distinguish symptomatic headache.
- For the new treatment of headache. Diagnosis in the primary care. Measures in the case of wavering in the judgement.
- For the new treatment of headache. Treatment in the primary care. Primary care for idiopathic headache. Pharmacotherapy and nerve block.
- For the new treatment of headache. Treatment in the primary care. Preventive control of headache.
- For the new treatment of headache. Treatment in the primary care. Measures for the headache fit.
- For the new treatment of headache. Treatment in the primary care. Guidance of drug administration and life guidance. From the viewpoint of the pharmacist.
- For the new treatment of headache. How is headache treatment carried out? From questionnairing to the pain clinic physician.
- Maxacalcitol. Oxarol.
- Alendronate sodium hydrate. Fosamac. Bonalon.
- Calcitriol. Rocaltrol.
- Practice of cancer pain treatment seen in the case. The third. Recent practical topics of the nociceptive pain treatment. Opioid rotation and treatment of bone metastasis pain.
- Nutritional administration to the cancer patient.
- From the consultation room. 58. A case of hypothyroidism which appeared under treatment of hypertension of the adult woman.
- Pharmacology for therapeutic planning. Antianxiety agent.
1
| Copyright (c) 2006-2007 Japan Science and Technology Agency. All Rights Reserved. | |
